{"symbol":"BMY","fiscalQuarter":"Q2-2025","reportDate":"2025-07-31","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2025","postBrief":{"headline":"Bristol Myers Squibb Misses on EPS \u2014 Stock Down 5.81%","keyNumbers":[{"metric":"EPS","actual":"$1.46","expected":"N/A","surprise":"-12.63%"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management acknowledged the challenges faced during the quarter.","They emphasized a focus on long-term strategies despite short-term setbacks."],"summary":"Management expressed concerns about current market conditions impacting performance. They reiterated their commitment to innovation and pipeline development."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a significant miss on EPS, which contributed to a 5.81% decline in stock price. Investors may be concerned about the company's current challenges and lack of guidance. The management's defensive tone suggests that they are aware of the hurdles ahead but remain focused on long-term growth strategies.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2025 earnings: EPS missed expectations. Stock down 5.81%. Full breakdown."}}